Betulinic acid / Cyt‑c Cancer Research Results

BetA, Betulinic acid: Click to Expand ⟱
Features:
Betulinic acid "buh-TOO-li-nik acid" is a natural compound with antiretroviral, anti malarial, anti-inflammatory and anticancer properties. It is found in the bark of several plants, such as white birch, ber tree and rosemary, and has a complex mode of action against tumor cells.
-Betulinic acid is a naturally occurring pentacyclic triterpenoid
-vitro concentrations range from 1–100 µM, in vivo studies in rodents have generally used doses from 10–100 mg/kg
Precursor: Betulin, via oxidation at C-28
Lipophilicity: High (poor aqueous solubility)

Betulinic acid — Betulinic acid is a naturally occurring lupane-type pentacyclic triterpenoid with broad experimental anticancer activity, especially against melanoma, neuroectodermal, glioma, breast, colorectal, and other solid-tumor models. It is a natural-product small molecule, usually abbreviated BA or BetA, and is found in several plants, classically birch bark, with semi-synthesis commonly starting from betulin. A distinguishing feature is preferential induction of tumor-cell death through direct mitochondrial injury with relative sparing of many non-neoplastic cells in preclinical systems. Its main translational limitation is very poor aqueous solubility with correspondingly weak oral/systemic developability unless formulation or derivatization is used.

Primary mechanisms (ranked):

  1. Direct mitochondrial membrane permeabilization with intrinsic apoptosis activation
  2. Mitochondrial ROS increase with collapse of mitochondrial membrane potential and cytochrome c release
  3. ER-stress and unfolded-protein-response activation, including GRP78-linked stress signaling
  4. Suppression of NF-κB and other pro-survival transcriptional programs, including Sp-family signaling in some models
  5. Cell-cycle arrest with reduced cyclin/CDK signaling
  6. Anti-migratory and anti-invasive effects via EMT, FAK, ROCK1, MMP, and cytoskeletal remodeling pathways
  7. Secondary metabolic suppression of aerobic glycolysis and hypoxia-response signaling in susceptible models
  8. Adjunct sensitization to chemo- or radiotherapy in selected preclinical settings

Bioavailability / PK relevance: Betulinic acid is highly lipophilic and poorly water-soluble, which strongly limits oral absorption and systemic exposure. PK behavior is formulation-dependent, and much of the translational literature focuses on nanoparticles, liposomes, micelles, conjugates, or topical delivery rather than conventional oral dosing.

In-vitro vs systemic exposure relevance: Many in-vitro anticancer studies use low-to-mid micromolar concentrations, which are often difficult to reproduce reliably in vivo with unformulated parent betulinic acid. Accordingly, mechanistic findings are useful biologically, but direct concentration matching to standard oral/systemic use is often poor unless enhanced-delivery systems are used.

Clinical evidence status: Strong preclinical and formulation-development literature; very limited human oncology evidence. Cancer-facing clinical development appears to remain early-phase/topical, with orphan designation for topical metastatic melanoma but no FDA approval for that indication. Betulinic acid itself is not an established approved anticancer drug.

-half-life reports vary 3-5 hrs?. Reported half-life varies by formulation and species; several studies report multi-hour systemic persistence.
BioAv -hydrophobic molecule with relatively poor water solubility. 
Main Cancer action
-Direct mitochondrial targeting in cancer cells
-Minimal effect on normal cells

Key pathways
-Mitochondrial membrane permeabilization
-ROS-mediated apoptosis
-Caspase-independent death

Chemo relevance: Generally compatible, Not a redox buffer

Pathways:
- often induce ROS production
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓
- Lowers AntiOxidant defense in Cancer Cells(Often associated with reduced redox buffering capacity in tumor cells (e.g., GSH depletion); NRF2 direction model-dependent.): NRF2↓, SOD↓, GSH↓
- May Raise AntiOxidant defense in Normal Cells: NRF2↑, SOD↑, GSH↑, Catalase↑ Reports suggest relative sparing of normal cells and preservation of antioxidant capacity in some models
- lowers Inflammation : NF-kB↓(typ), COX2↓, p38↓ (context-dependent; often stress-activated), Pro-Inflammatory Cytokines : IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : , MMPs↓, MMP2↓, MMP9↓, TIMP2, IGF-1↓, VEGF↓, ROCK1↓, FAK↓, NF-κB↓, TGF-β↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : P53↑, HSP↓(model-dependent), Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, CDK2↓, CDK4↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, FAK↓, ERK↓, EMT↓, TOP1↓,
- inhibits glycolysis (secondary to mitochondrial stress) ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, HK2↓, ECAR↓, GRP78↑(ER stress), GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, EGFR↓,
- inhibits Cancer Stem Cells in some studies : CSC↓, GLi1↓, β-catenin↓, OCT4↓,
- Others: PI3K↓(typ), AKT↓(typ), JAK↓, STAT↓, β-catenin↓, AMPK↓(AMPK is often activated during metabolic stress), ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,
- Selectivity: Cancer Cells vs Normal Cells

Mechanistic profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial permeabilization ↑ MOMP, ↓ ΔΨm, ↑ cytochrome c release, ↑ apoptosis ↔ / milder effect P-R Core tumor-selective death trigger Best-supported central mechanism; helps explain activity in apoptosis-competent but therapy-resistant tumors.
2 Mitochondrial ROS increase ↑ ROS ↔ / possible antioxidant sparing (context-dependent) P-R Amplifies mitochondrial stress and death signaling ROS appears mechanistically relevant in many tumor models, but not every study makes it the dominant initiating event.
3 Caspase axis and caspase-independent death ↑ caspase-9, ↑ caspase-3, ↑ PARP cleavage; caspase-independent death also reported ↔ R-G Executes apoptosis after mitochondrial injury BA can still kill some tumor cells when classical caspase execution is partly blocked, indicating non-canonical death contribution.
4 ER stress / UPR / GRP78 ↑ ER stress, ↑ UPR, ↑ GRP78 stress signaling ↔ R-G Links proteostatic stress to apoptosis and metastasis suppression Especially relevant in breast and gastric cancer models; may also connect to metabolic suppression and chemosensitization.
5 NF-κB survival signaling ↓ NF-κB ↔ / ↓ inflammatory tone R-G Reduces survival, inflammatory, and resistance programs Common downstream convergence node across several tumor types.
6 Cell-cycle machinery ↓ cyclin D1, ↓ CDK2, ↓ CDK4, ↑ cell-cycle arrest ↔ G Slows proliferation Usually supportive rather than primary; often follows stress and survival-pathway disruption.
7 EMT / invasion / matrix remodeling ↓ EMT, ↓ FAK, ↓ ROCK1, ↓ MMP2, ↓ MMP9, ↓ migration, ↓ invasion ↔ G Antimetastatic effect Consistent with reduced motility and invasive phenotype in multiple solid-tumor models.
8 Glycolysis ↓ glucose uptake, ↓ lactate, ↓ ECAR, ↓ HK2, ↓ PKM2, ↓ LDHA ↔ G Secondary metabolic suppression Not the universal initiating mechanism; appears important in selected breast-cancer and GRP78-linked systems.
9 HIF-1α hypoxia axis ↓ HIF-1α, ↓ VEGF, ↓ GLUT1, ↓ PDK1 ↔ G Reduces hypoxic adaptation and angiogenic drive Relevant in hypoxic tumor biology and helps explain antiangiogenic/metabolic effects in some models.
10 NRF2 / antioxidant buffering ↓ NRF2 or ↓ redox buffering (model-dependent) ↔ / possible preservation of antioxidant tone (context-dependent) R-G May widen tumor redox vulnerability Direction is not uniform across all models; safer to treat this as contextual rather than universally core.
11 Ca²⁺ stress ↑ Ca²⁺ (context-dependent) ↔ P-R Supports organelle stress and apoptotic signaling Usually part of the broader mitochondrial/ER stress network rather than a stand-alone primary target.
12 Radiosensitization or Chemosensitization ↑ sensitivity to radiation or selected drugs Unclear G Adjunct leverage Preclinical evidence supports additive or sensitizing effects with irradiation and with some chemotherapy settings, but this is not yet clinically established.
13 Clinical Translation Constraint Poor solubility and limited systemic exposure constrain reproducibility Same formulation constraint G Delivery bottleneck Main barrier is not lack of mechanistic richness but drug-like exposure; translation currently depends heavily on formulation, derivatization, or topical/local use.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (primary/physical-chemical effects; rapid kinase/redox signaling)
  • R: 30 min–3 hr (acute redox and stress-response activation)
  • G: >3 hr (gene-regulatory adaptation and phenotypic outcomes)
Cyt‑c, cyt-c Release into Cytosol: Click to Expand ⟱
Source:
Type:
Cytochrome c
** The term "release of cytochrome c" ** an increase in level for the cytosol.
Small hemeprotein found loosely associated with the inner membrane of the mitochondrion where it plays a critical role in cellular respiration. Cytochrome c is highly water-soluble, unlike other cytochromes. It is capable of undergoing oxidation and reduction as its iron atom converts between the ferrous and ferric forms, but does not bind oxygen. It also plays a major role in cell apoptosis.

The term "release of cytochrome c" refers to a critical step in the process of programmed cell death, also known as apoptosis.
In its new location—the cytosol—cytochrome c participates in the apoptotic signaling pathway by helping to form the apoptosome, which activates caspases that execute cell death.
Cytochrome c is a small protein normally located in the mitochondrial intermembrane space. Its primary role in healthy cells is to participate in the electron transport chain, a process that helps produce energy (ATP) through oxidative phosphorylation.
Mitochondrial outer membrane permeability leads to the release of cytochrome c from the mitochondria into the cytosol.
The release of cytochrome c is a pivotal event in apoptosis where cytochrome c moves from the mitochondria to the cytosol, initiating a chain reaction that leads to programmed cell death.

On the one hand, cytochrome c can promote cancer cell survival and proliferation by regulating the activity of various signaling pathways, such as the PI3K/AKT pathway. This can lead to increased cell growth and resistance to apoptosis, which are hallmarks of cancer.
On the other hand, cytochrome c can also induce apoptosis in cancer cells by interacting with other proteins, such as Apaf-1 and caspase-9. This can lead to the activation of the intrinsic apoptotic pathway, which can result in the death of cancer cells.
Overexpressed in Breast, Lung, Colon, and Prostrate.
Underexpressed in Ovarian, and Pancreatic.
Scientific Papers found: Click to Expand⟱
2760- BetA,    A Review on Preparation of Betulinic Acid and Its Biological Activities
- Review, Var, NA - Review, Stroke, NA
AntiTum↑, Cyt‑c↑, Smad1↑, Sepsis↓, NF-kB↓, ICAM-1↓, MCP1↓, MMP9↓, COX2↓, PGE2↓, ERK↓, p‑Akt↓, *ROS↓, *LDH↓, *hepatoP↑, *SOD↑, *Catalase↑, *GSH↑, *AST↓, *ALAT↓, *RenoP↑, *ROS↓, *α-SMA↓,
2752- BetA,    Betulinic acid: a natural product with anticancer activity
- Review, Var, NA
selectivity↑, ChemoSen↑, RadioS↑, MMP↓, cl‑Casp3↑, Cyt‑c↑, ROS↑, NF-kB↑, TOP1↓,
2748- BetA,    Betulinic Acid: Recent Advances in Chemical Modifications, Effective Delivery, and Molecular Mechanisms of a Promising Anticancer Therapy
- Review, Var, NA
Bcl-2↓, MMP↓, Cyt‑c↑, Casp↑, Diablo↑, AIF↑, angioG↓, BioAv↓, NF-kB↓,
2747- BetA,    Betulinic acid, a natural compound with potent anticancer effects
- Review, Var, NA
selectivity↑, Cyt‑c↑, *toxicity↓, TOP1↓, NF-kB↓, ROS↑, RadioS↑, ChemoSen↑,
5592- BetA,    Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells
- in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa
Casp3↑, Casp9↑, cl‑PARP↑, Apoptosis↑, Cyt‑c↑, MMP↓,
5591- BetA,    Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment
- Review, BC, NA
BioAv↓, BioAv↑, selectivity↑, eff↑, angioG↓, *antiOx↑, *Inflam↓, MMP↓, Bcl-2↓, BAX↑, Casp9↑, Casp3↑, GRP78/BiP?, ER Stress↑, PERK↑, CHOP↑, ChemoSen↑, SESN2↑, ROS↑, MOMP↓, MAPK↑, Cyt‑c↑, AIF↑, STAT3↓, FAK↓, TIMP2↑, TumCMig↓, TumCI↓, Sp1/3/4↓, TumCCA↑, DNAdam↑,
5584- BetA,    Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors
- in-vitro, GBM, A172 - in-vitro, GBM, U118MG - in-vitro, GBM, U251
Apoptosis↑, P53↑, Cyt‑c↑, AIF↑, Casp↑, AntiTum↑, MMP↓,
5582- BetA,    Targeting mitochondrial apoptosis by betulinic acid in human cancers
- Review, Var, NA
Apoptosis↑, MMP↓, Cyt‑c↑, ROS↑, NF-kB↑, angioG↓, mtDam↑, TOP1↓, selectivity↑, ChemoSen↑, TumCG↓, chemoPv↑, RadioS↑,
2722- BetA,    Betulinic Acid for Cancer Treatment and Prevention
- Review, Var, NA
MMP↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp8↑, ROS↑, NF-kB↑, TOP1↓,
2729- BetA,    Betulinic acid in the treatment of tumour diseases: Application and research progress
- Review, Var, NA
ChemoSen↑, mt-ROS↑, STAT3↓, NF-kB↓, selectivity↑, *toxicity↓, eff↑, GRP78/BiP↑, MMP2↓, P90RSK↓, TumCI↓, EMT↓, MALAT1↓, Glycolysis↓, AMPK↑, Sp1/3/4↓, Hif1a↓, angioG↓, NF-kB↑, NF-kB↓, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, RadioS↑, PERK↑, CHOP↑, *toxicity↓,
2718- BetA,    The anti-cancer effect of betulinic acid in u937 human leukemia cells is mediated through ROS-dependent cell cycle arrest and apoptosis
- in-vitro, AML, U937
TumCCA↑, Apoptosis↑, i-ROS↑, cycA1/CCNA1↓, CycB/CCNB1↓, P21↑, Cyt‑c↑, MMP↓, Bax:Bcl2↑, Casp9↑, Casp3↑, PARP↓, eff↓, *antiOx↑, *Inflam↓, *hepatoP↑, selectivity↑, NF-kB↓, *ROS↓,
2717- BetA,    Betulinic Acid Induces ROS-Dependent Apoptosis and S-Phase Arrest by Inhibiting the NF-κB Pathway in Human Multiple Myeloma
- in-vitro, Melanoma, U266 - in-vivo, Melanoma, NA - in-vitro, Melanoma, RPMI-8226
Apoptosis↑, TumCCA↑, MMP↓, ROS↑, eff↓, NF-kB↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP1↑, MDA↑, SOD↓, SOD2↓, GCLM↓, GSTA1↓, FTH1↓, GSTs↓, TumVol↓,
2743- BetA,    Betulinic acid and the pharmacological effects of tumor suppression
- Review, Var, NA
ROS↑, MMP↓, Cyt‑c↑, Apoptosis↑, TumCCA↑, Sp1/3/4↓, STAT3↓, NF-kB↓, EMT↓, TOP1↓, MAPK↑, p38↑, JNK↑, Casp↑, Bcl-2↓, BAX↑, VEGF↓, LAMs↓,
2736- BetA,  Chemo,    Multifunctional Roles of Betulinic Acid in Cancer Chemoprevention: Spotlight on JAK/STAT, VEGF, EGF/EGFR, TRAIL/TRAIL-R, AKT/mTOR and Non-Coding RNAs in the Inhibition of Carcinogenesis and Metastasis
- Review, Var, NA
chemoPv↑, p‑STAT3↓, JAK1↓, JAK2↓, VEGF↓, EGFR↓, Cyt‑c↑, Diablo↑, AMPK↑, mTOR↓, Sp1/3/4↓, DNAdam↑, Gli1↓, GLI2↓, PTCH1↓, MMP2↓, MMP9↓, miR-21↓, SOD2↓, ROS↑, Apoptosis↑,
2735- BetA,    Betulinic acid as apoptosis activator: Molecular mechanisms, mathematical modeling and chemical modifications
- Review, Var, NA
mt-Apoptosis↑, Casp↑, p38↑, MAPK↓, JNK↓, VEGF↓, AIF↑, Cyt‑c↑, ROS↑, Ca+2↑, ATP↓, NF-kB↓, ATF3↓, TOP1↓, VEGF↓, survivin↓, Sp1/3/4↓, MMP↓, ChemoSen↑, selectivity↑, BioAv↓, BioAv↑, BioAv↑, BioAv↑, BioAv↑,
2732- BetA,  Chemo,    Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
ChemoSen↑, selectivity↑, GRP78/BiP↑, ER Stress↑, PERK↑, Ca+2↑, Cyt‑c↑, BAX↑, Bcl-2↓,

Showing Research Papers: 1 to 16 of 16

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 16

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ATF3↓, 1,   GCLM↓, 1,   GSTA1↓, 1,   GSTs↓, 1,   MDA↑, 1,   ROS↑, 9,   i-ROS↑, 1,   mt-ROS↑, 1,   SOD↓, 1,   SOD2↓, 2,  

Metal & Cofactor Biology ⓘ

FTH1↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 4,   ATP↓, 1,   MMP↓, 12,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 2,   Glycolysis↓, 1,  

Cell Death ⓘ

p‑Akt↓, 1,   Apoptosis↑, 7,   mt-Apoptosis↑, 1,   BAX↑, 3,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Casp↑, 4,   Casp3↑, 5,   cl‑Casp3↑, 2,   Casp8↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 5,   Cyt‑c↑, 16,   Diablo↑, 2,   JNK↓, 1,   JNK↑, 1,   MAPK↓, 1,   MAPK↑, 2,   MOMP↓, 1,   p38↑, 2,   survivin↓, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 5,  

Transcription & Epigenetics ⓘ

miR-21↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   ER Stress↑, 2,   GRP78/BiP?, 1,   GRP78/BiP↑, 2,   PERK↑, 3,  

Autophagy & Lysosomes ⓘ

SESN2↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,   P53↑, 1,   PARP↓, 1,   cl‑PARP↑, 1,   cl‑PARP1↑, 1,  

Cell Cycle & Senescence ⓘ

cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   P21↑, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 2,   ERK↓, 1,   Gli1↓, 1,   mTOR↓, 1,   P90RSK↓, 1,   PTCH1↓, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   TOP1↓, 6,   TumCG↓, 1,  

Migration ⓘ

Ca+2↑, 2,   FAK↓, 1,   GLI2↓, 1,   LAMs↓, 1,   MALAT1↓, 1,   MMP2↓, 2,   MMP9↓, 2,   Smad1↑, 1,   TIMP2↑, 1,   TumCI↓, 2,   TumCMig↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 4,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   ICAM-1↓, 1,   JAK1↓, 1,   JAK2↓, 1,   MCP1↓, 1,   NF-kB↓, 9,   NF-kB↑, 4,   PGE2↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 5,   ChemoSen↑, 7,   eff↓, 2,   eff↑, 2,   RadioS↑, 4,   selectivity↑, 8,  

Clinical Biomarkers ⓘ

EGFR↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 2,   chemoPv↑, 2,   TumVol↓, 1,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 100

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 1,   GSH↑, 1,   ROS↓, 3,   SOD↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   LDH↓, 1,  

Migration ⓘ

α-SMA↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 2,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

hepatoP↑, 2,   RenoP↑, 1,   toxicity↓, 3,  
Total Targets: 15

Scientific Paper Hit Count for: Cyt‑c, cyt-c Release into Cytosol
16 Betulinic acid
2 Chemotherapy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:42  Target#:77  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page